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The current classification of cutaneous malignant lymphomas (ML) into low-grade 
and high-grade lymphomas was found to be of limited reproducibility and 
permitted only a rough prediction about outcome. With this in mind, the 
relationship between nuclear DNA content and both prognosis and histologic 
grading according to the Kiel classification was evaluated on Feulgen-stained 
imprint specimens. In all, 49 cases of malignant non-Hodgkin's lymphoma, primary 
of the skin or with an involvement of the skin as one of the first symptoms, were 
studied using a computerized high-resolution image analysis system. The 2c 
deviation index (ZcDI), which reflects the variation of the nuclear DNA values 
around the normal diploid peak, was found to be the best prognostically relevant 
criterion. Using the ZcDI, a significant discrimination (P less than 0.001 in the U 
test) between low-grade and high-grade ML was achieved. The prognostic benefit of 
the 2cDI was well documented by a significant inverse correlation between the 2cDI 
and the period of time until the patients progressed at least into one higher stage or 
died of lymphoma (r equals -0.63, P less than 0.05). In addition, the 2cDI enabled 
prognosis of the course of disease. In the group with low 2cDI values (ZcDI, less 
than 0.5), no progression of the disease was observed after 1 year. In the groups 
presenting with a 2cDI between 0.5 and 1.0 and higher than 1.0, a progression was 
found in 57% and 64% of the cases studied, respectively. In conclusion, these 
measurements indicate that the determination of DNA distribution patterns in 
imprint specimens allows a precise and objective prognostic evaluation of 
cutaneous ML. Cancer 68:1095-1100,1991. 
H E  CORRECT GRADING Of skin infiltrates in CUta- T neous malignant lymphomas (ML) is an important 
prerequisite for selection of the most appropriate therapy. 
Currently, morphologic classification systems, such as the 
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Kiel classification,] allow only a rough discrimination be- 
tween low-grade and high-grade ML, which may not re- 
flect the full range of biologic Grading of 
lymphomas according to morphologic features alone also 
is subjective and was shown to be insufficiently repro- 
d ~ c i b l e . ~ , ~  Moreover, approximately 15% of cutaneous 
ML do not fit into common classification  scheme^.^ 
This was demonstrated in one study4 where there was 
identification of four prognostically relevant subgroups in 
mycosis fungoides (MF) alone: some of these cases had 
the same poor prognosis as high-grade lymphomas. In 
addition to histologic and immunohistologic findings, 
more objective and reliable criteria are necessary for an 
accurate prognostic evaluation of individual cases of ML. 
It is widely accepted that malignant tumors often have 
abnormal nuclear DNA values and that DNA measure- 
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ments are very helpful for the prognostic and diagnostic 
evaluation of neoplasms of many To our 
knowledge, measurements of Feulgen-stained (Merk, 
Darmstadt, Germany) nuclei were used only for the di- 
agnosis of cutaneous ML,I4-l7 not for the determination 
of prognostically relevant markers. Therefore, we used 
high-resolution image analy~is'".'~ of imprint preparations 
of cutaneous ML to examine the prognostic significance 
of DNA cytometry and its relationship to histologic 
grading. 
Materials and Methods 
Patients 
The DNA measurements were done on imprint prep- 
arations of skin lesions of 49 cases of malignant non- 
Hodgkin's lymphoma, primary of the skin or with an in- 
volvement of the skin as one of the first symptoms. The 
diagnoses were established by histologic, immunohisto- 
logic, and clinical criteria before DNA analysis. Because 
the Kiel classification' was not found to be reliable for 
grading of all low-grade malignant  lymphoma^,^ cases with 
a predominance of medium-sized or large lymphocytes 
in the infiltrate were classified by two independent well- 
trained histopathologists into a group of intermediate 
grades of malignancy (Table 1). According to this modified 
Kiel classification,' 23 of 49 cases were classified as low- 
grade malignant lymphomas (1 2 of B-cell type and 1 1 of 
T-cell type); ten cases, as intermediate-grade (six of T-cell 
type, one of B-cell type, and three unclassified cases), and 
16 as high-grade lymphomas (two of T-cell type, eight of 
B-cell type, four of neither B-cell nor T-cell types, and 
two unclassified cases; Table 1). 
Detailed staging procedures were done, including chest 
radiography, computed tomography, sonography, and if 
necessary, radionuclide imaging, and biopsies were taken 
of the bone marrow, liver, and lymph nodes. Stages were 
defined according to the tumor-node-metastasis (TNM) 
system.' Detailed data concerning diagnosis, histologic 
type, grading, age, and sex are given in Table 1.  
The interval between imprint preparation and pro- 
gression to the next higher stage in the TNM system or 
death was known for I8 of the 49 patients. In these cases, 
it was possible to study the correlation between DNA data 
and progression. 
Preparation of Imprints 
Imprints were made by touching clean glass slides with 
the freshly cut surface of a skin biopsy specimen. Fixation 
of the imprints with methanol (loo%), formaldehyde 
(37%), and glacial acetic acid (96%) 85: 105 (v/v/v) and 
Feulgen staining were done according to Bohm.20 The 
imprints were hydrolyzed with 5 N HCl for 50 minutes 
at a constant temperature of 28°C and stained with Schiff s 
reagent for 60 minutes. 
DNA Measurements 
DNA analysis was done on the imprints using the high- 
resolution video image-analysis system IPS (Kontron, 
Eching, Germany). The routine for DNA measurements 
(described in detail previously)2' allows a fully automatic 
segmentation of the nuclear area by using different steps 
of image processing such as gray-scale normalization and 
high-pass filtering. 
Variables Calculated 
For each nucleus, the optical density (OD) and the area 
were measured. The integrated optical density (IOD) was 
obtained by multiplying the OD by the area. In Feulgen- 
stained nuclei, the IOD is correlated linearly with the DNA 
content. Twenty chicken erythrocytes were used as an 
internal reference on each slide. In a previous pilot study, 
a comparison of nuclei of chicken erythrocytes and nor- 
mal human lymphocytes revealed that: 
IODe,*3.26 = 2~ DNAlymphocytes (1B) 
The 2c DNA represents the DNA content of a normal 
human diploid cell. A euploid cell in G2 contains 4c DNA. 
In this study, the relative DNA content of 100 randomly 
selected cells was calculated in each case as follows: 
Relative DNA content = IODnucleus/IODlcDNA (2B) 
Algorithms for Data Evaluation 
The discriminating power of the following features of 
the DNA histogram was evaluated using the Kontron 
software package: 
The 2c deviation index (2cDI): The 2cDI was defined 
according to Backing el aL2* as the ratio between the sum 
of the squares of the differences between the DNA values 
of individual cells (ci) and the 2c value and the number 
of cells measured (N). 
l N  
N i-1 
(3B) 
Roughly, the 2cDI reflects the variation of the nuclear 
DNA values around the 2c value for an individual patient. 
The 5c  exceeding rate (ScER): The 5cER was defined 
according to Bocking et a1.22 as the percentage of cells 
with a DNA content equal to or more than 5c. Because 
euploid-polyploid cells should not contribute to the ScER, 
all cells with DNA values that are integer-valued expo- 
nents of 2c * 12.5% are ignored. The maximum error of 
measurement was set at 12.5%.22 Thus, the 5cER identifies 
aneuploid cells only. 
2cDI = - 2 (c, - 2 ~ ) ~  
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TABLE 1. Patient Characteristics 
Grade of Patient 
malignancy* no. Age (yr)/sex Histologic diagnosis 2cDI 4cER (9’0) ScER (%) 
Low-grade 1 76M CLL-B 0.05 0 0 
2 52F MF I 0.05 0 0 
3 40M IC 0.09 1 0 
4 58F IC 0.1 1 9 0 
5 65M CBCC 0.14 4 0 
6 69M ss 0.24 2 0 
7 62M M F  III 0.28 2 0 
8 59F M F I I  0.29 2 1 
9 76F CBCC 0.3 I 0 0 
10 59M M F  I 0.3 I 3 0 
11 75F M F  I1 0.32 3 0 
12 63M IC 0.32 3 1 
13 59M CBCC 0.34 2 1 
14 45M M F  I 0.37 5 0 
15 75M CLL-T 0.37 1 1 
16 71M M F  I 0.39 5 1 
17 34M ss 0.40 6 0 
18 53F MF-I1 0.4 1 4 1 
19 36M CBCC 0.50 4 1 
20 73M CBCC 0.50 4 1 
21 75M IC 0.57 6 0 
22 37F CBCC 0.77 5 4 
23 65F CBCC 0.8 1 12 0 
Intermediate-grade 24 56M UC-ML 0.43 4 1 
25 65F M F  Ill 0.62 7 1 
26 71M uc-ML 0.65 9 0 
27 58M CBCC 0.85 6 0 
28 66M M F  111 0.96 5 0 
29 79M uc-ML I .05 12 2 
30 70M M F  I11 1.07 10 1 
31 73M M F  111 1.15 10 2 
32 40F M F  11 1.18 12 4 
33 72F M F  111 1.68 15 0 
34 67M UC-ML 0.53 10 0 
35 73F LBL 0.55 7 0 
36 72F CBL 0.56 7 0 
37 77F LBL-B 0.68 8 0 
38 78F IBL-B 0.73 1 0 
39 52M CBL 1 .oo 7 0 
40 64M LBL I .03 6 0 
41 67M IBL 1.31 8 0 
42 37M CBL 1.39 8 0 
43 46M IBL 2.0 1 17 2 
44 43F IBL-T 2.09 21 0 
45 37M UC-ML 2.97 37 1 
46 75F LBL-B 3.84 8 3 
47 66F CBL 5.99 27 10 
48 70M LBL-T 10.50 45 7 
49 57M CBL 11.73 84 5 
High-grade 
2cD1: 2c deviation index; 4cER: 4c exceeding rate; ScER: 5c exceeding 
rate; CLL-B: chronic lymphatic leukemia, B-cell type; MFI: mycosis 
fungoides, premycotic lesion; IC: immunocytoma; CBCC: centroblastic- 
centrocytic lymphoma; SS: Sezary syndrome; MF 111: mycosis fungoides, 
tumor lesion; MF 11: mycosis fungoides, plaque lesion; CLL-T: chronic 
lymphatic leukemia, T-cell type; uc-ML: unclassified malignant lym- 
The 4c exceeding rate (4cER): For the classification of 
benign and malignant lesions, van Vloten et aP4 used 
the percentage of cells with a DNA value higher than 4c. 
They classified a lesion as malignant if more than 5% of 
the cells contained 4c DNA or more. 
phoma; LBL: lymphoblastic lymphoma; CBL: centroblastic lymphoma; 
LBL-B: lymphoblastic lymphoma, B-cell type; IBL-B: immunoblastic 
lymphoma, B-cell type; IBL: immunoblastic lymphoma; IBL-T: im- 
munoblastic lymphoma, T-cell type; LBL-T: lymphoblastic lymphoma, 
T-cell type. 
* According to a modified Kiel classification. 
Data Analysis 
Statistical evaluation of the data was based on the 
Mann-Whitney’s U test and the correlation ~oeff ic ient .~~ 
Significance in both tests was defined as P less than 0.05. 









The reproducibility of DNA measurements was tested four 
times during the study by the demonstration of the dif- 
ferent ploidy peaks in rat liver imprints. 
Results 
The best discrimination between low-grade and high- 
grade lymphomas was possible using the 2cDI (Fig. 1). In 
the group of low-grade lymphomas, the 2cDI ranged from 
0.05 to 0.8 I ;  in high-grade lymphomas, 2cDI values from 
0.53 to 1 1.73 were observed. In the intermediate group, 
the 2cD1 was between 0.43 and 1.68. Statistically signif- 
icant differences were found between low-grade and high- 
grade ML ( P  less than 0.00 I), between intermediate-grade 
and low-grade ML (P less than O.OOl), and between the 
intermediate-grade and high-grade ML ( P  less than 0.05). 
No significant differences were found between B-cell and 
T-cell lymphomas in either the low-grade or the inter- 
mediate-grade or high-grade groups of ML ( P  more than 
0.05). The determination of the 4cER also allowed sig- 
nificant discrimination between low-grade and interme- 
diate-grade ML ( P  less than 0.001), but not between the 
intermediate-grade and high-grade groups ( P  more than 
0.05). The 4cER values ranged from 0 to 12 in low-grade, 
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FIG. I .  Correlation between grading into low-grade, intermediate-grade, 
and high-grade malignant lymphomas and 2c deviation index. 
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FIG. 2. Significant correlation ( r  = -0.63) between the period (log,, 
months) until progression into the next higher TNM stage or death and 
the 2c deviation index. 
ML. Significant differences were not observed for the 
5cER. Values between 0 and 4 were found in the low- 
grade and intermediate-grade groups and between 0 and 
10, in high-grade ML. 
Not only was 2cDI a useful marker for differentiating 
between low-grade and high-grade ML; but the formula 
log,,(2cDIt 1 )  showed a significant inverse correlation ( r  
equals -0.63, P less than 0.05) to loglO(time) until pro- 
gression to the next higher stage of the TNM scheme or 
death occurred. This also was found for low-grade lym- 
phomas (Kiel) alone ( r  equals 0.68, P less than 0.05); for 
high-grade lymphomas (Kiel), the correlation was not sig- 
nificant. For B-cell lymphomas alone, the correlation 
coefficient was even higher ( r  equals -0.75, Fig. 2). 
In addition, the 2cDI was a predictor of the course of 
the disease. None of the patients with a 2cDI lower than 
0.5 had tumor progression within 1 year, whereas 57% 
and 64% of the patients with a 2cDI from 0.5 to 1.0 or 
higher than 1 .O, respectively, had to be assigned to a higher 
TNM stage after I year. Simultaneously, the percentage 
of patients with a remission under therapy decreased in 
the groups with higher 2cDI values (Fig. 3). 
The 2cDI also was useful for the prediction of mortality. 
In the group with initial 2cDI values below 0.5, all patients 
were still alive after 2 years, whereas the mortality rate 
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FIG. 3. Percentage of patients with remission, no change, and pro- 
gression of the disease after I year of adequate therapy for the three 
prognostic groups defined according to the 2c deviation index. 
was 30% in the group with a 2cDI between 0.5 and 1.0 
and 45% in patients with a 2cDI exceeding 1 .O. 
The 2cD1 showed a significant correlation with both 
the 4cER ( I  equals 0.92, P less than 0.05) and the 5cER 
( r  equals 0.79, P less than 0.05). However, the 5cER and 
the 4cER did not provide additional prognostic infor- 
mation. 
Discussion 
The most impressive result in this cytometric study was 
the finding that calculation of the 2cDI allowed a signif- 
icant discrimination between low-grade, intermediate- 
grade, and high-grade lymphomas using a modified Kiel 
classification (P less than 0.05, by two-sided U test, Fig. 
I ). Applying the 4cER as a criterion for grading, a differ- 
ence was obtained between low-grade and high-grade 
lymphomas, but not between intermediate-grade and 
high-grade lymphomas because the zone of overlap be- 
tween the groups was higher than using the 2cDI. The 
ScER, which represents the percentage of cells containing 
more than 5c DNA and is therefore an indicator for def- 
inite aneuploidy, was found to be an unreliable marker 
for grading. The 5cER seems to be more useful for the 
differentiating between benign and malignant lesions, as 
shown for cutaneous pseudolymphomas and malignant 
lymphomas,*’ and for tumors of the breast, bone, prostate, 
and 
A prerequisite for grading strategies in the Kiel 
classification’ or the New Working Formulation for clin- 
ical usage of the National Cancer Institute24 is that his- 
tomorphologically similar lymphomas have the same 
malignant potential. However, morphologically defined 
subgroups of malignant lymphomas often are heteroge- 
neous in their clinical course and do not always have the 
same survival pr~bability.’-~ Different prognostically rel- 
evant subgroups of MF were defined because, with respect 
to survival probability, cases with many large and medium 
cells were more likely to represent high-grade than low- 
grade  lymphoma^.^ However, a major handicap for the 
broad application of such detailed classification strategies4 
is the low interobserver reproducibility.6 In contrast to 
morphologic grading, the 2cDI is a more objective and 
reproducible parameter.*-3 
Moreover, the currently applied histopathologic clas- 
sification schemes, such as the Kiel classification or the 
New Working Formulation, allow discrimination only 
between two or three prognostic relevant groups. The 2cDI 
provides a continuous scale for grading of malignancy of 
individual lesions and has been established as a sensitive 
feature for grading and diagnosis of tumors of the bone, 
cervix, breast, prostate, and nodular  lymphoma^.',^.^' To 
our knowledge, the prognostic impact of DNA distribution 
pattern has not been demonstrated in cutaneous ML. 
The calculation of the 2cDI using imprint investigation 
with an image-analysis system does not require a well- 
trained histopathologist with great experience in the field 
of ML; it can be done with the same accuracy by a tech- 
nician. However, the procedure is more time consuming 
than detailed histopathologic examination. 
The relevance of this newly described grading parameter 
for cutaneous ML has to be demonstrated by its clinical 
impact. We found a significant correlation between the 
10g,~(2cDI+ 1) and the loglo of the time elapsed until the 
next higher TNM stage was reached or death occurred. 
This correlation also was significant in the low-grade group 
alone. This indicates a heterogeneous prognosis in a mor- 
phologically defined subgroup and stresses the advantage 
of the 2cDI for prognostic evaluation. In these low-grade 
cases, 5cER was always lower than 576, and the benefit of 
the 2cDI was not based on the presence of numerous 
aneuploid nuclei with DNA values higher than 5c, but 
on the increase of proliferative nuclei with relative DNA 
values between 2 . 2 5 ~  and 3 . 5 ~ .  Because ofthe low number 
of high-grade lymphomas with sufficient prognostic data, 
a significant correlation could not be calculated in these 
cases. Using the regression line in Figure 2, the individual 
risk ofthe patients can be determined more precisely than 
by applying the rough discrimination into low-grade, in- 
termediate-grade, and high-grade lymphomas. Moreover, 
without respect to histomorphology, the 2cDI enabled 
discrimination between three groups of patients with dif- 
ferent progression rates (Fig. 3). 
The nuclear area frequently is well correlated with the 
nuclear DNA content,*’ and morphometric techniques 
alone (which can be done more rapidly already using low- 
cost image analysis systems or point sampling methods 
as described recently for malignant melanomas)26 also 
might be clinically beneficial. In the Netherlands, a mul- 
ticenter study was begun to evaluate the benefits of mor- 
phometric measurements in histologic sections of breast 
cancer.*’ These authors showed that about 22% of patients 
received a more appropriate therapy with than without 
morphometric data. 
Cytochemical and immunologic cell typing28-35 also 
might allow a more detailed prognostic analysis in cuta- 
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neous ML. One study described the use of the monoclonal 
antibody Ki-67, reported to be well correlated with the 
growth fraction of cell populations, which therefore might 
be an additional predictor of prognosis in human tu- 
m o r ~ . ~ ’  Using the Ki- 1 antibody, a new and distinct entity 
among the cutaneous lymphomas was defined that could 
not be characterized by morphologic features alone.33 
However, for most of the cutaneous malignant lympho- 
mas, prognostically significant antibodies are of limited 
value, and further experience must be gained with this 
te~hnique.’~ For evaluating the full benefit of DNA mea- 
surements for predicting prognosis in cutaneous ML, as 
indicated by our study, long-term prospective and retro- 
spective studies of more patients are necessary. Such in- 
vestigations already have been done for mammary 
adenocarcinomal’ and nodular lymph~ma.’.~ 
The development of techniques for the production of 
single-cell specimens from paraffin-embedded material36 
now has made these studies easier. High-resolution image 
analysis of the chromatin structure, altered even in pre- 
neoplastic therefore may be superior to pure 
ploidy analysis and may improve the grading of ML. 
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